




07025974



Our ref.: 04/1049

3 August 2007

The US Securities and Exchange Commission  
Division of Corporation Finance  
450 5<sup>th</sup> Street N.W.  
Washington D.C. 20549  
USA

**SUPPL**

Attention: Division of Corporate Finance (International)  
Mail Stop 3 - 9

Dear Sir/Madam

**CSL ANNOUNCEMENT**

Please find attached a copy of the Announcement CSL made to the market on 27 July.

*US Food and Drug Administration approves Privigen™  
First Proline-stabilized 10 percent liquid IVIG*

Yours faithfully,

**Peter Turvey  
COMPANY SECRETARY**

**PROCESSED**

**B AUG 16 2007  
THOMSON  
FINANCIAL**

Enc



# ASX Announcement

27 July 2007

## **US Food & Drug Administration approves Privigen™ First Proline-stabilized 10 percent liquid IVIG**

Melbourne Australia: CSL Limited announced today that its subsidiary CSL Behring, has been granted marketing approval from the U.S. Food and Drug Administration (FDA) for Privigen™ [Immune Globulin Intravenous (Human) 10% Liquid], an intravenous immunoglobulin (IVIg) for treating patients diagnosed with primary immunodeficiency (PI). Privigen is also indicated for the treatment of chronic immune thrombocytopenic purpura (ITP) to rapidly raise platelet counts to prevent bleeding.

A 10 percent liquid preparation of polyvalent human immunoglobulin, Privigen offers healthcare professionals convenience and ease-of-use. It is the first and only proline-stabilized IVIg that is always ready for immediate use, requiring no refrigeration or reconstitution.

CSL Behring plans to launch Privigen in the first quarter of 2008, which is consistent with previous expectations. In the meantime, the company is advancing the registration of Privigen in Europe. The application is currently under review by European regulatory authorities.

For further information, please contact:

Mark Dehring  
Head of Investor Relations  
CSL Limited Telephone: +613 9389 2818  
Email: [mark.dehring@csl.com.au](mailto:mark.dehring@csl.com.au)

**END**